Target intelligence / Profile preview

Lysosomal cathepsin (CTS) (CTS)

Target
CTS
Molecular classification
Enzyme, Protease, Hydrolase, Cysteine protease, Aspartic protease
01

Overview

Lysosomal cathepsins are a family of proteases, predominantly cysteine proteases, that function within the acidic environment of lysosomes to degrade and recycle intracellular and endocytosed proteins (Stoka et al., 2016). While they are essential for cellular homeostasis, specific members of the family play specialized roles, such as Cathepsin K in bone resorption and Cathepsin S in MHC class II-mediated antigen presentation (Yadati et al., 2020). In diseases like cancer, cathepsins are often upregulated and secreted into the extracellular matrix, where they facilitate tumor invasion and metastasis by degrading structural proteins (Olson & Joyce, 2015). They also serve as critical host factors for the entry of several viruses, including Ebola and SARS-CoV-2, by processing viral glycoproteins (Bojkova et al., 2020). Therapeutic strategies have focused on small-molecule inhibitors to treat osteoporosis, inflammatory disorders, and malignancies, though achieving selectivity remains a significant hurdle due to the high structural similarity among family members (Vizovisek et al., 2019). Clinical development of some inhibitors, such as the Cathepsin K inhibitor Odanacatib, was halted due to safety concerns including an increased risk of stroke and skin-related adverse events (Mullard, 2016).

Other names
Cathepsin familyLysosomal proteaseLysosomal cysteine proteaseCysteine cathepsinAspartic cathepsin
02

Mechanism of action

Small-molecule inhibition of the proteolytic activity of specific cathepsin enzymes to prevent substrate degradation or viral processing (Yadati et al., 2020).

03

Biological functions

Protein degradationAutophagyAntigen presentationApoptosisBone remodelingPro-enzyme activationExtracellular matrix degradation
04

Disease associations

CancerOsteoporosisInflammationNeurodegenerative diseaseCardiovascular diseaseViral infectionRheumatoid arthritis
05

Safety considerations

Increased risk of stroke (observed with Odanacatib) (Mullard, 2016)Skin adverse events such as morphea-like lesions (Rock et al., 2014)Off-target inhibition of related proteases due to high structural homologyPotential for lysosomal storage-like symptoms
06

Interacting drugs

Odanacatib

6 more in the full profile.

07

Biomarkers

Serum Cathepsin B levelsSerum Cathepsin S levelsC-terminal telopeptide of type I collagen (CTX-I)Cathepsin K activity levels

Beyond the preview

Go deeper on Lysosomal cathepsin (CTS) (CTS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysosomal cathepsin (CTS) (CTS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call